Multiple sclerosis trials recruiting in Illinois

All Multiple sclerosis trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
  NCT06587828 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Skokie
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago, Evanston, Urbana
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• An Individualized-health eLibrary App for People With Multiple Sclerosis
  NCT05124600 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Champaign
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
  NCT04047628 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Illinois: Evanston
• Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
  NCT06390930 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
  NCT07132775 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device
  NCT06410261 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
  NCT05051618 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · Illinois: Chicago
• Fall Prevention Among People With Spinal Cord Injury and Multiple Sclerosis Who Use Wheelchairs and Scooters
  NCT07167680 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Urbana
• Functional Balance Intervention in Multiple Sclerosis
  NCT06341023 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• Home Based Functional Balance Intervention for Multiple Sclerosis
  NCT07355387 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 90 Years · Sex: All (male and female) · Illinois: Chicago
• Intermittent Hypoxia in Persons With Multiple Sclerosis
  NCT06276634 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Nomad P-KAFO Study
  NCT05644522 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 89 Years · Sex: All (male and female) · Illinois: Chicago
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Illinois: Northbrook
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
  NCT05285891 · Phase: Phase 4 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Illinois: Chicago
• Ocrevus Zunovo for MS: Mixed Methods
  NCT07710105 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
  NCT07207148 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
  NCT06655896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Chicago
• Remote Evaluation of MIND Diet
  NCT06450977 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · Illinois: Urbana
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · Illinois: Chicago
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Illinois: Chicago
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• TSC Biosample Repository and Natural History Database
  NCT05676099 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Illinois: Chicago
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
  NCT07225361 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago